Calcium Ionic Compound for Cachexia Muscle Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cachexia, a complex syndrome associated with diseases like cancer, tuberculosis, and heart failure, are inadequate as they often lead to temporary weight gain followed by loss and have adverse effects, highlighting the need for a new approach that addresses the multifactorial mechanisms of muscle loss and energy metabolism.
Innovation Solution
A pharmaceutical and food composition containing a calcium-based ionic compound with ascorbic acid, dichloroacetic acid, and branched-chain amino acids, which acts multimodally to inhibit catabolism, maintain muscle homeostasis, and reduce muscle loss by regulating energy metabolism, inflammatory factors, and appetite suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional treatments (nutritional supplementation or appetite enhancers) are used to treat cachexia, then weight may temporarily increase, but the weight decreases again and physical ability is not improved
Solution Approach 1:
The patent changes the chemical parameters of the treatment by using a specific ionic compound composition (calcium with ascorbic acid, dichloroacetic acid, and BCAA anions) instead of conventional nutritional supplements or appetite enhancers. This parameter change in treatment composition addresses the multifactorial mechanisms of cachexia including catabolism, muscle homeostasis disruption, and inflammatory factors, leading to sustained weight gain and improved physical ability
Solution Approach 2:
The patent employs a composite ionic compound containing calcium cation combined with multiple different anions (ascorbic acid, dichloroacetic acid, and branched-chain amino acid anions). This composite structure allows the treatment to act multimodally on various pathological mechanisms of cachexia simultaneously, providing sustained therapeutic effect rather than temporary weight gain followed by loss
2Quantity of substance
If conventional treatments (megestrol acetate or long-term nutritional supplementation) are used, then appetite may be enhanced or weight may increase, but adverse effects occur such as erectile dysfunction, uterine bleeding, thromboembolism, edema, hyperglycemia, adrenal insufficiency, and hypertension
Solution Approach 1:
The patent changes the pharmacological parameters by replacing megestrol acetate (a progestin with multiple adverse effects) with a naturally-derived ionic compound composition. This parameter change eliminates the harmful side effects while maintaining the therapeutic effect of weight gain and appetite enhancement through a safer mechanism that addresses cachexia's underlying causes
Solution Approach 2:
The patent uses naturally occurring substances (vitamin C, dichloroacetic acid, branched-chain amino acids) that are metabolized and eliminated without accumulation, replacing long-acting pharmaceuticals with adverse effects. These components are processed by normal metabolic pathways, avoiding the persistence and toxicity issues of conventional drugs
3Device complexity
If a single-anion calcium compound is used, then the treatment mechanism is simple, but it cannot address the multifactorial mechanisms of cachexia effectively
Solution Approach 1:
The patent employs a composite ionic compound with calcium cation and multiple different anions (ascorbic acid, dichloroacetic acid, and branched-chain amino acid anions). This composite structure enables multimodal action on various pathological mechanisms of cachexia including catabolism inhibition, muscle homeostasis maintenance, and inflammatory factor regulation, providing reliable therapeutic effectiveness
Solution Approach 2:
The patent designs the ionic compound to perform multiple functions simultaneously: ascorbic acid anion provides antioxidant activity, dichloroacetic acid anion inhibits catabolism, and BCAA anion supports muscle protein synthesis. This multi-functionality allows a single compound to address the multifactorial mechanisms of cachexia effectively
Data Source
AI summary
The present disclosure provides a pharmaceutical composition and a food composition for preventing or treating cachexia and muscle loss, wherein the pharmaceutical composition and the food composition each comprise an ionic compound that comprises a calcium cation, a first anion, and a second anion, and wherein the first anion and the second anion are different from each other, and are each independently anions of ascorbic acid, dichloroacetic acid, a branched-chain amino acid (BCAA), or derivatives thereof.